Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionRafferty Asset Management, LLC
Latest Disclosed Ownership36,232 shares
Latest Disclosed Value $ 4,773,204
Rafferty Asset Management, LLC reports 7.23% decrease in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Rafferty Asset Management, LLC filed a 13F-HR form disclosing ownership of 36,232 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $4,773,204 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 39,055 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -7.23% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 36,232 -2,823 -7.23 4,773 -13.83 0.0194
2026-02-13 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 39,055 -19,646 -33.47 5,539 -32.78 0.0191
2025-11-12 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,701 -20,445 -25.83 8,240 -17.16 0.0267
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 79,146 -21,661 -21.49 9,948 -10.78 0.0328
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,807 -6,204 -5.80 11,149 -23.67 0.0475
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 107,011 -33,824 -24.02 14,607 -9.98 0.0517
2024-11-13 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 140,835 17,837 14.50 16,227 -4.17 0.0556
2024-08-13 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 122,998 57,128 86.73 16,933 86.40 0.0629
2024-05-13 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,870 -10,679 -13.95 9,085 -9.93 0.0339
2024-02-13 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 76,549 -4,941 -6.06 10,086 10.03 0.0425
2023-11-13 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 81,490 -7,541 -8.47 9,168 9.20 0.0539
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 89,031 18,043 25.42 8,396 16.84 0.0473
2023-05-11 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 70,988 2,334 3.40 7,185 -12.38 0.0487
2023-02-13 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 68,654 3,525 5.41 8,200 18.55 0.0687
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,129 24,727 61.20 6,917 75.65 0.0736
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 40,402 -19,494 -32.55 3,938 -29.87 0.0362
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 59,896 -6,304 -9.52 5,615 -0.41 0.0333
2022-02-10 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 66,200 33,986 105.50 5,638 82.46 0.0297
2021-11-10 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 32,214 5,764 21.79 3,090 20.05 0.0211
2021-08-10 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 26,450 -7,886 -22.97 2,574 -22.91 0.0162
2021-05-10 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,336 24,002 232.26 3,339 236.93 0.0228
2021-02-10 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 10,334 -9,432 -47.72 991 -47.87 0.0097
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,766 8,621 77.35 1,901 39.78 0.0230
2020-08-07 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,145 6,864 160.34 1,360 266.58 0.0192
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,281 -31,334 -87.98 371 -90.31 0.0155
2020-02-10 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 35,615 -31,629 -47.04 3,828 -36.82 0.0589
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 67,244 8,325 14.13 6,059 21.79 0.0948
2019-08-09 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 58,919 -5,611 -8.70 4,975 -12.49 0.0875
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 64,530 64,530 5,685 0.0915
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.